Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
469.27
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
63
64
Next >
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
↗
April 11, 2024
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures...
Via
Benzinga
Topics
Economy
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
↗
April 11, 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
Via
InvestorPlace
Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock
↗
April 11, 2024
Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts.
Via
InvestorPlace
Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts
↗
April 11, 2024
An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack.
Via
InvestorPlace
Vertex Pharmaceuticals: Buy, Sell, or Hold?
↗
April 11, 2024
The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?
Via
The Motley Fool
1 Top Growth Stock to Buy and Hold Forever
↗
March 31, 2024
This drugmaker looks unstoppable.
Via
The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today
↗
March 25, 2024
Via
Benzinga
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
↗
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
↗
April 11, 2024
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Via
Investor's Business Daily
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
↗
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to...
Via
Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
↗
April 11, 2024
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons
Via
Benzinga
Topics
Economy
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
↗
April 10, 2024
The companies expect the deal to close later this quarter.
Via
Investor's Business Daily
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
↗
April 09, 2024
This innovative machine rolls on.
Via
The Motley Fool
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
↗
April 09, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over
Via
Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
↗
April 09, 2024
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.
Via
InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
↗
April 09, 2024
These companies are close to launching new products that could supercharge revenue.
Via
The Motley Fool
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
↗
April 05, 2024
These businesses are booming.
Via
The Motley Fool
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
↗
April 01, 2024
All three companies have very long runways for growth ahead.
Via
The Motley Fool
Meet The "Magnificent Seven" of Healthcare Stocks
↗
April 01, 2024
The tech sector doesn't have a monopoly on magnificent corporations.
Via
The Motley Fool
2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years
↗
March 31, 2024
Great businesses are here to stay. These are two excellent examples.
Via
The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
↗
March 30, 2024
These stocks have exceptionally bright prospects.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
March 28, 2024
Via
Benzinga
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
↗
March 28, 2024
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.
Via
Investor's Business Daily
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
↗
March 26, 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.
Via
InvestorPlace
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
↗
March 25, 2024
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Via
InvestorPlace
3 Biopharma Stocks Predicted to Soar in Q2 2024
↗
March 20, 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals.
Via
InvestorPlace
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
↗
March 19, 2024
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.
Via
InvestorPlace
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
↗
March 17, 2024
It's always a good time to buy great stocks with excellent prospects.
Via
The Motley Fool
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
↗
March 17, 2024
There's no need for delays in buying these great stocks.
Via
The Motley Fool
Forget Tesla, Buy This Magnificent Healthcare Stock Instead
↗
March 17, 2024
Vertex Pharmaceuticals already has a fantastic business, and it could get much bigger in the future.
Via
The Motley Fool
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
63
64
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today